PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver - Pediatric
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Drug Studies
Contact Us
Log In
You need to enable JavaScript to run this app page.
Leukemia
TCH-AML002
Model Details
Patient
PDX Model
Histology
Metastasis
Patient Treatment
Patient Information for Model: TCH-AML002
Contact Model Developer
Model Contact
Model: TCH-AML002
Model Contact: Alexandra Stevens
Institution: TCH Leukemia PDX Program
Email:
amsteven@texaschildrens.org
Patient Information
Clinical Timeline
Clinical Information at Collection
Clinical Biomarkers/Mutations
Model Information for Model: TCH-AML002
Model Details - Initial Implantation of Patient Tissue
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Histology Information for Model: TCH-AML002
There are no histology images for this model.
Metastasis Information for Model: TCH-AML002
Patient
PDX
Abdomen
BM
Central Nervous System
Face
Gingiva
Kidney
Kidneys
L cheek
Leg
Liver
Lymph node
Orbital chloroma
PB
Pancreas
Periorbital
Retinas
Skin
Skull base
Spine
Spleen
Stomach
Tail
Temporal bone
Testis
Tongue
periorbital chloroma
sacrum
Patient Treatment Information for Model: TCH-AML002
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
Measurable Residual Disease
10
Cytarabine/Idarubicin
De Novo
20.06
Unknown
Induction Failure
15
Cytarabine/Fludarabine
Refractory
20.25
Unknown
Residual Disease
20
clo/topotecan/vinorelbine/thiotepa
Refractory
20.37
Unknown
Residual Disease
25
azacitidine/venetoclax
Refractory
20.54
Unknown
30
venetoclax
Refractory
20.66
Unknown
Remission
.16%
50
decitabine/venetoclax then DLI
Relapse
21.3
Unknown
Relapse
14%
60
decitabine/venetoclax then DLI
Relapse
21.4
Unknown
Relapse
4%
Please wait...
